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example is inflammation: perhaps the sim-
plest form of pathology. It has well defined 
characteristics which, for many of the old 
continent, were described in latin: rubor, 
tumor, calor, dolor, and functio lesa. When 
these characteristics are present, the pathol-
ogy/disease can be diagnosed. If it occurs 
in the lung it will indicate pneumonia, in 
the kidney nephritis etc. Likewise, a brain 
chronically receiving drugs changes its 
physiology, its biochemistry, and even its 
anatomy in its most intimate structure such 
as dendritic spines and genes. An excellent 
example (but many other exist) is provided 
by one of the most intensely studied neu-
ronal systems of the brain in addiction stud-
ies: the dopamine system.
Neurobiology
This system is profoundly hypofunctional 
after being targeted by chronic drugs of 
abuse (Melis et al., 2005): electrophysi-
ological activity is reduced (Diana et al., 
1993, 1995, 1998), release is hampered and 
cell bodies shrink (Spiga et al., 2003). On 
the postsynaptic side similar changes occur 
and spine density loss has been documented 
in amphetamine-experienced (Robinson 
and Kolb, 1997, 2004), alcohol-dependent 
(Diana et al., 2003), morphine-withdrawn 
(Spiga et al., 2005), and cannabis-addicted 
rodents (Spiga et al., 2010). Human stud-
ies (key to validate animal models) are 
equally informative and supportive of a 
compromised role of DA transmission in 
human addicts. For instance, while alcohol 
increases DA release in healthy subjects 
(Boileau et al., 2003) with some gender 
differences (Urban et al., 2010), a reduced 
number of DA receptors has been observed 
(Volkow et al., 1996; Martinez et al., 2005) in 
alcoholics that appears to be accompanied 
by a blunted DA release (Martinez et al., 
2005, 2007; Volkow et al., 2007). While the 
reduced number of DA receptors could be, 
at first sight, be viewed as suggesting an 
DefiNiNg ADDictioN
Classification of behavioral disturbances 
should be done by carefully considering the 
boundaries between physiology (normal-
ity) and pathology (disease), irrespective 
of social context. The following considera-
tions will highlight some of the objectivable 
changes observed in the brains of animals 
and humans who underwent repetitive use 
of addicting chemicals. These molecular, 
cellular, and even structural, carefully doc-
umented and widely reproduced, changes, 
which take place at the level of the brain, 
form the basis for classifying addiction as 
a brain disease, as defined in DSM IV-R. 
Attributing to addiction the status of dis-
ease has several advantages and virtually no 
disadvantage. The first, major advantage is 
for the sufferer/addict himself: it confers 
automatically the status of patient and 
excludes another status, frequently attrib-
uted to him by societal custom: delinquent. 
Another advantage is that research on the 
biological basis of a widespread disease such 
as addiction will continue to be fostered by 
(desperately needed) public funding and, 
hopefully, efficient therapies will be found. 
Addiction is a brain disease which impairs 
behavior: the product of brain activity. As 
such should be classified, studied, treated, 
and hopefully cured. The whole society will 
benefit from it.
levy’s ApproAch
In his essay Levy (2013) approaches the 
problem of addiction (without providing 
a definition) in a mixed way providing a 
mostly sociological perspective that leads 
him to conclude that addiction is not a brain 
disease. I will argue that this is not the way 
the problem should be approached. I was 
taught early (as a medical student) in my 
life that a disease (pathology) is a derail-
ment from normal functioning of a system/
organ/cell (physiology), and ultimately of 
the whole organism. A frequently employed 
augmented DA release, it should be noted 
that by administering the DA inhibitor 
alpha methyl-para-tyrosine, Martinez et al. 
(2009) were able to exclude this possibil-
ity. Indeed, while healthy controls do show 
an increased raclopride binding after acute 
alpha methyl-para-tyrosine administration, 
cocaine-dependent subjects do not (or to a 
significantly lesser extent). Similar results 
were obtained with the dopamine releasing 
agent methylphenidate (Volkow et al., 2007) 
and amphetamine (Martinez et al., 2005) 
in alcoholics. Notably, artificially increasing 
the brain levels of DAD2 receptors, using a 
replication-deficient adenoviral vector con-
taining the rat cDNA insert for DAD2 into 
the Nacc, reduces alcohol intake in spon-
taneously drinking rats, thereby offering 
Popper-style evidence that a potentiation of 
DA transmission may have beneficial effects 
on alcohol-seeking and alcohol-taking 
(Thanos et al., 2001, 2004). In line with this 
conclusion, a spontaneous high number of 
DA D2 receptors has been shown to have a 
protective role in non-alcoholic members 
of alcoholic families (Volkow et al., 2006). 
These findings further support the notion 
that the number of DA receptors (and con-
sequently DA transmission) inversely cor-
relates with alcohol pathological drinking.
NeurAl plAsticity
Among the various points Levy raises is: “It 
will not help the defender of the brain disease 
account to add the other neural correlates asso-
ciated with addiction into the mix. Consider 
the chronic deviation from reward set point 
suggested by Koob and Le Moal (1997, 
2008). The allostatic state they postulate is 
the result of the brain  adapting to drug inges-
tion. So long as the drug is  reliably  available, 
the person will suffer no ill-effects from this 
neuroadaptation. Rather, the anhedonic 
state from which individuals suffer is associ-
ated with chronic abstinence. Identifying the 
pathology with this  unpleasant state entails, 
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status. Further, let’s take for example 
malaria (i.e, jungle fever). It is well known 
that fever peaks every 3–4 days depend-
ing on the plasmodium strain. Should we 
then conclude that the patient has malaria 
only when his temperature rises every 3 or 
4 days? Clearly, the patient is afflicted by 
malaria even when the fever is gone and 
body temperature is normal.
In the case of addiction, its inclusion in 
brain disorders may bear even broader con-
sequences. Many abused drugs are illegal in 
the western world and thus any individual 
dealing with these compounds (heroin, 
cocaine, amphetamines etc) is susceptible of 
imprisonment or, in the best cases, may be 
found guilty of use with consequent social 
stigma. However, if the addict is considered 
a patient he will “gain” a status, as antici-
pated earlier, free of moral connotations.
In conclusion, drug addiction is a medi-
cal condition attributed to an individual 
which has been assuming chemicals whose 
pharmacological effects produce a new 
brain equilibrium, called pathology. It can 
be documented in various ways (see above) 
thereby justifying the disease label. The 
organ afflicted is mainly (but not only) the 
brain and its fundamental byproduct (i.e., 
behavior) is severely diseased.
Denying its classification as a disease 
would be like precluding a patient his/her 
right to be cured.
reAsoNiNg
A final consideration: what strikes most in 
Levy’s account is that he spends many efforts 
in attempting to persuade the readership of 
what addiction “is not” whereas no effort is 
dedicated to describe what addiction actu-
ally “is.” At least in his mind. His statement: 
“these correlates are not sufficient for the 
person to have a disease in some accessible 
environments” represent, in my opinion, 
the “logic jump” in his flawed reasoning.
If we admit that the neural correlates of 
addiction are pathological (see above), and 
we admit that behavior stems from these 
neural correlates, it goes without saying 
that pathological neural correlates will yield 
pathological behavior (addiction). This 
conclusion can easily be inferred by invok-
ing both deductive (facts are determined 
by combining existing statements) and 
inductive reasoning (facts are determined 
by repeated observations). Nowadays, we 
are well aware that both types of reasoning 
counter-intuitively, that the abstinent addict 
suffers from a pathology but the addict who 
is using does not.”
First: intuition is not a form of learning 
that is neurobiologically recognized and 
thus what Levy finds “counterintuitive” may 
simply be due to his personal expectations 
instead than stemming from observation of 
objective experimental facts. The allostatic 
concept of Koob and Le Moal (2008) simpli-
fied, says that the addicted brain is “stiffer” 
and less prone to adapt to homeostasis 
(equilibrium). Familiarizing with the neural 
plasticity concept could help: in poor words, 
brain plasticity allows the system (the brain) 
to adapt to new situations which include 
the drug of abuse (tolerance). It adapts to 
the new situation by implementing mecha-
nisms to reduce harm that may be produced 
by the intruder (drug) which result in a 
new physiological status. If the drug is now 
abruptly removed from the system, then the 
suffering becomes evident with a number of 
signs and symptoms which characterize the 
withdrawal syndrome. Almost paradoxi-
cally, but only at first sight, in the addicted 
individual the drug works as a trophic fac-
tor that helps the whole system to function. 
When the trophic factor is removed the dis-
ease is unveiled.
Second: as long as the drug of choice is 
available the addict will not suffer because 
the drug itself is the “cure” of his pathol-
ogy. Examples of this fact have been known 
for decades in the field and exemplified by 
methadone for opiate-addicts, nicotine 
patches for tobacco-dependent individuals 
and GHB for alcoholics (Gallimberti et al., 
1989; Biggio et al., 1992). The problem 
emerges when the drug is NO longer avail-
able and the withdrawal syndrome ensues 
from it. This should not be seen as a bizarre 
or a curious event but is actually the rule 
in many medical instances. For example, 
diabetics suffer because their pancreas does 
not produce insulin, whose absence (if not 
compensated exogenously) may bring the 
patient to hyperglycemic coma. Similarly, 
in the addict, homeostasis is reached when 
the drug is “on-board” and not when the 
drug is withdrawn. Actually, withdrawal is a 
key phase of the whole addicting cycle (see 
Koob and Volkow, 2010). Not only this is 
the phase in which the addict will mani-
fest a full-blown discomfort but is also the 
only phase in which he will seek treatment 
and will admit, possibly, his  pathological 
present different fallacies, but when both 
coincides “it is difficult to argue against 
facts, unfortunately ….”1
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